The NFL is unquestionably one of the most successful American businesses of all-time. Surprisingly, though, the NFL's 2013 revenues were no match for this single legal drug.
Three Motley Fool contributors explain why they don't want these large-cap biotech companies to pay a dividend.
AbbVie, Amgen, and Pfizer are three dividend stocks that could crush the broader market this year. Here's why.
AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?
Gilead Sciences, Amgen, and Biogen Idec could be the best biotech stocks to buy.
Celgene Corporation, Amgen Inc., and Gilead Sciences may all offer long term opportunity if markets falter.
AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.
Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.
8 out of 10 of last year's best-performing stocks have this one important common denominator.
Gilead Sciences looks cheap based on its present valuation metrics and growth prospects going forward. Will a growth-starved big pharma decide to pursue a merger with this high flying biotech in 2015?